Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
89bio logo — Developing and commercializing innovative therapies for the...

89bio

Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases

Founded 2018 United States San Francisco, United States 123 employees Post Ipo Equity Total: $773.20M Biopharma, Biotechnology +1

General Information

Company Name 89bio
Founded Year 2018
Location United States San Francisco, United States +1
Employees 123
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when 89bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About 89bio

89bio

89bio is a clinical-stage biopharmaceutical company with a focus on developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases. Their lead product candidate, BIO89-100, is an engineered glycoPEGylated analog of FGF21 designed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company's recent Phase 1b/2a data showed favorable safety and tolerability profiles and significant reductions in liver fat and key lipid markers in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. Founded in 2018 and headquartered in San Francisco with operations in Herzliya, Israel, 89bio upholds a strong set of values, including prioritizing patient needs, integrity, authenticity, teamwork, entrepreneurship, and scientific rationality.

The company's last investment of $150.00M in post-IPO equity occurred on 06 December 2023.

Taxonomy: biopharmaceutical company, clinical-stage, FGF21 analog, NASH treatment, SHTG treatment, liver diseases, cardio-metabolic diseases, innovative therapies, Phase 2 trial, patient-centric, ethical standards, scientific advancement, San Francisco, Herzliya, Israel

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 06 Dec 2023
Post-IPO Equity •••••• - 24 Mar 2023
Post-IPO Debt •••••• 1
Investor
04 Jan 2023
Post-IPO Equity •••••• - 28 Jun 2022
Post-IPO Secondary •••••• - 14 Jul 2020

View All 7 Funding Rounds

89bio Alternatives & Competitors

89bio vs
Roche
Roche Switzerland

We advance science so that we all have more time with the people we love. Are you ready to join us?

IPO
108149 employees
Pharmaceutical
Compare 89bio vs Roche
89bio vs
Synta Pharmaceuticals
Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, includ...

Post Ipo Equity
Biotechnology, Health Care
Compare 89bio vs Synta Pharmaceuticals
89bio vs
Kinarus Therapeutics
Kinarus Therapeutics Switzerland

Kinarus Therapeutics is a clinical-stage company developing therapies for viral, respiratory and ocu...

Post Ipo Equity
5 employees
Biopharma, Biotechnology
Compare 89bio vs Kinarus Therapeutics

FAQ About 89bio

Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases
89bio was founded in 2018.
89bio is headquartered in San Francisco, United States.
89bio operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
89bio has approximately 123 employees.
89bio has completed 7 funding rounds, raising a total of $773.20M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to 89bio include Roche, Synta Pharmaceuticals, Kinarus Therapeutics, Roche, Spark Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
89bio and Roche are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors 89bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes